Q-omics provides the consensus-scored C10orf88B profile across patient tissues and cancer cell-line models. C10orf88B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C10orf88B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, C10orf88B RNA expression shows 19,712 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where C10orf88B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf88B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf88B survival associations across molecular data types. C10orf88B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf88B RNA expression–survival associations across cancer types. High C10orf88B expression shows unfavorable associations in KIRP, MESO, ACC, LIHC and KIRC, but favorable associations in UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C10orf88B RNA expression.
This table summarizes C10orf88B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C10orf88B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf88B shows higher tumor expression in HNSC, LUAD, STAD, BLCA, KIRP and COAD. The HNSC box plot shows higher C10orf88B RNA expression in tumor versus normal tissue (log2 FC = +0.816, t-test p < 0.001).
This table shows molecular features associated with C10orf88B in patient tissues and cancer cell lines. In patient samples, C10orf88B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
